Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure

Summary

In patients with atrial fibrillation (AF) who require interruption of dabigatran or warfarin for an elective surgery/procedure, the risks and benefits of perioperative bridging anticoagulation is uncertain. We accessed the database from RE-LY, a randomised trial comparing dabigatran with warfarin for stroke prevention in AF, to assess the potential benefits and risks of bridging. In patients who had a first interruption of dabigatran or warfarin for an elective surgery/procedure, we compared the risk for major bleeding (MB), stroke or systemic embolism (SSE) and any thromboembolism (TE) in patients who were bridged or not bridged during the period of seven days before until 30 days after surgery/procedure. We used multivariable Cox regression to adjust for potential confounders. Bridging was used more during warfarin interruption than dabigatran interruption (27.5 % vs 15.4 %; p < 0.001). With dabigatran interruption, bridged patients had more MB (6.5 % vs 1.8 %, p < 0.001) than those not bridged but bridged and not bridged groups did not differ for any TE (1.2 % vs 0.6 %, p=0.16) and SSE (0.5 % vs 0.3 %, p=0.46). With warfarin interruption, bridged patients had more MB (6.8 % vs 1.6 %, p < 0.001) and any TE (1.8 % vs 0.3 %, p=0.007) than those not bridged but bridged and not bridged groups did not differ for SSE (0.5 % vs 0.2 %, p=0.321). In conclusion, in patients who interrupted dabigatran or warfarin for a surgery/ procedure in the RE-LY trial, use of bridging anticoagulation appeared to increase the risk for major bleeding irrespective of dabigatran or warfarin interruption.

Keywords

Bridging anticoagulation - surgery - dabigatran - warfarin

• References

• 1 Douketis JD. et al. Perioperative management of antithrombotic therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012; 141: e326S-350S.
• 2 van Ryn J. et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
• 3 Spyropoulos AC, Douketis JD. How i treat anticoagulated patients undergoing an elective procedure or surgery. Blood 2012; 120: 2954-2962.
• 4 Birnie DH. et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. New Engl J Med 2013; 368: 2084-2093.
• 5 Connolly SJ. et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 2009; 361: 1139-1151.
• 6 Healey JS. et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: Results from the randomized evaluation of long-term anticoagulation therapy (re-ly) randomized trial. Circulation 2012; 126: 343-348.
• 7 Granger CB. et al. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med 2011; 365: 981-992.
• 8 Patel MR. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med 2011; 365: 883-891.
• 9 Giugliano RP. et al. Edoxaban versus warfarin in patients with atrial fibrillation. New Engl J Med 2013; 369: 2093-2104.
• 10 Go AS. et al. Heart disease and stroke statistics--2013 update: A report from the american heart association. Circulation 2013; 127: e6-e245.
• 11 Stangier J. et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: An open-label, parallel-group, single-centre study. Clin Pharmacokin 2010; 49: 259-268.
• 12 Douketis JD. et al. The perioperative management of antithrombotic therapy: American college of chest physicians evidence-based clinical practice guidelines (8th ed.). Chest 2008; 133: 299S-339S.
• 13 Spyropoulos AC. et al. Periprocedural antithrombotic and bridging therapy: Recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy. J Thromb Haemost 2012; 10: 692-694.
• 14 Gage BF. et al. Validation of clinical classification schemes for predicting stroke: Results from the national registry of atrial fibrillation. J Am Med Assoc 2001; 285: 2864-2870.
• 15 Levey AS. et al. Definition and classification of chronic kidney disease: A position statement from kidney disease: Improving global outcomes (kdigo). Kidney Int 2005; 67: 2089-2100.
• 16 Wunsch H. et al. Methods to adjust for bias and confounding in critical care health services research involving observational data. J Crit Care 2006; 21: 1-7.
• 17 Lip GY. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272.
• 18 Pisters R. et al. A novel user-friendly score (has-bled) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010; 138: 1093-1100.
• 19 Omran H. et al. The has-bled score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre bnk online bridging registry (border). Thromb Haemost 2012; 108: 65-73.
• 20 Schulman S, Crowther MA. How i treat with anticoagulants in 2012: New and old anticoagulants, and when and how to switch. Blood 2012; 119: 3016-3023.
• 21 Douketis JD. Pharmacologic properties of the new oral anticoagulants: A clinician-oriented review with a focus on perioperative management. Curr Pharma-ceut Design 2010; 16: 3436-3441.
• 22 Tafur AJ. et al. Predictors of major bleeding in peri-procedural anticoagulation management. J Thromb Haemost 2012; 10: 261-267.
• 23 Dunn A. Perioperative management of oral anticoagulation: When and how to bridge. J Thromb Thrombol 2006; 21: 85-89.
• 24 Siegal D. et al. Periprocedural heparin bridging in patients receiving vitamin k antagonists: Systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 2012; 126: 1630-1639.
• 25 Kovacs MJ. et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004; 110: 1658-1663.
• 26 Dewilde WJ. et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. Lancet 2013; 381: 1107-1115.
• 27 Kaatz S. et al. Risk of stroke after surgery in patients with and without chronic atrial fibrillation. J Thromb Haemost 2010; 8: 884-890.
• 28 Harrison RW. et al. To bridge or not to bridge: These are the questions. J Thromb Thrombol 2012; 34: 31-35.
• 29 Spyropoulos AC, Ortel TL. Antithrombotic therapy and invasive procedures. New Engl J Med 2013; 369: 1078.
• 30 Skeith L. et al. Device surgery without interruption of anticoagulation. New Engl J Med 2013; 369: 1570-1571.
• 31 Vanassche T. et al. Heparin bridging in peri-procedural management of new oral anticoagulant: A bridge too far?. Eur Heart J. 2014 Epub ahead of print.
• 32 Liew A, Douketis J. Perioperative management of patients who are receiving a novel oral anticoagulant. Intern Emerg Med 2013; 8: 477-484.
• 33 Healey JS, Brambatti M. Periprocedural management of oral anticoagulation in patients with atrial fibrillation: Approach in the era of new oral anticoagulants. Canad J Cardiol 2013; 29: S54-59.
• 34 Ferrandis R. et al. The perioperative management of new direct oral anticoagulants: A question without answers. Thromb Haemost 2013; 110: 515-522.
• 35 Beyer-Westendorf J. et al. Peri-interventional management of novel oral anticoagulants in daily care: Results from the prospective Dresden NOAC registry. Eur Heart J. 2014 Epub ahead of print.